Celgene plans to submit sNDA by end of 2019
Celgene plans additional studies with the AIDS Malignancy Consortium
in U.S. and sub-Saharan Africa
SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and
Drug Administration (FDA) has granted Breakthrough Therapy designation
to POMALYST® (pomalidomide) for the treatment of patients with human
immunodeficiency virus (HIV)-positive Kaposi sarcoma who have previously
received systemic chemotherapy, as well as patients with HIV‐negative
Kaposi’s sarcoma.
Kaposi sarcoma is a multicentric tumor caused by Kaposi
sarcoma-associated herpesvirus, also called human herpesvirus-8.
Patients suffer multiple lesions on the skin and oral mucosa, and at
times other organs such as the lungs or gastrointestinal mucosa. Kaposi
sarcoma most commonly arises in persons infected with HIV. There is a
substantial need for new treatments because there are no approved
therapies for HIV-positive patients who are refractory to or intolerant
of systemic chemotherapy. Although the use of combination
anti-retroviral treatments (cART or HAART) has reduced the incidence of
advanced Kaposi sarcoma in the United States, there are still nearly
2000 new cases each year. The disease is more highly prevalent in areas
of the world where HIV treatments are less available, such as
sub-Saharan Africa, and in some countries is the most common tumor in
men overall.
“The encouraging news of the FDA Breakthrough Therapy designation for
POMALYST in Kaposi sarcoma reflects the urgency in accelerating the
development of therapies to address diseases of this type,” said Jay
Backstrom, M.D., Chief Medical Officer for Celgene. “We will continue to
work closely with the agency to move this program forward for patients
with this rare and serious cancer.”
The Breakthrough Therapy designation was granted by the FDA on the basis
of the results of a clinical study performed under a Cooperative
Research and Development Agreement (CRADA) by a team led by Dr. Robert
Yarchoan, of the HIV and AIDS Malignancy Branch within the Center for
Cancer Research of the National Cancer Institutes (NCI). The results of
that study, published in the Journal of Clinical Oncology (MN Polizzotto
et al, JCO, 2016, 34, 4125-31), evaluated POMALYST in patients with
Kaposi sarcoma, with or without HIV infection, many of whom had received
prior cytotoxic chemotherapy.
According to the FDA, Breakthrough Therapy designation is intended to
expedite the development and review of medicines with early evidence of
potential clinical benefit in serious diseases.
Celgene plans to submit a supplemental New Drug Application for POMALYST
in this disease area by the end of 2019.
Celgene also has two additional studies planned in this disease. In
partnership with the AIDS Malignancy Consortium (AMC), a U.S.
multicenter study will be performed to confirm and extend the results of
the NCI study. The AMC is also sponsoring a second study in sub-Saharan
Africa, where Kaposi sarcoma continues to be a serious problem. This
program is a part of the Celgene Global Health effort to discover and
develop new drugs for diseases that affect patients in the lower- and
middle-income countries where health systems and medical resources are
less advanced.
POMALYST is not approved for Kaposi sarcoma in any country.
About POMALYST
POMALYST is one of Celgene’s IMiD® agents – proprietary small
molecule, orally-available compounds for the treatment of some blood
cancers. IMiD agents are hypothesized to have multiple mechanisms of
action and have become a foundation of multiple myeloma research, with a
growing number of studies exploring these compounds in different
settings and diseases.
U.S. Safety Information
Indication
POMALYST® (pomalidomide) is a thalidomide analogue indicated,
in combination with dexamethasone, for patients with multiple myeloma
who have received at least two prior therapies including lenalidomide
and a proteasome inhibitor and have demonstrated disease progression on
or within 60 days of completion of the last therapy.
|
Important Safety Information |
|
WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL Embryo-Fetal Toxicity
POMALYST is only available through a restricted distribution Venous and Arterial Thromboembolism
|
CONTRAINDICATIONS
-
- Pregnancy: POMALYST can
cause fetal harm and is contraindicated in females who are pregnant.
If POMALYST is used during pregnancy or if the patient becomes
pregnant while taking this drug, the patient should be apprised of the
potential risk to a fetus.
- Pregnancy: POMALYST can
WARNINGS AND PRECAUTIONS
-
- Embryo-Fetal Toxicity & Females of
Reproductive Potential: See Boxed WARNINGS
- Embryo-Fetal Toxicity & Females of
-
- Males: Pomalidomide is present in the
semen of patients receiving the drug. Males must always use a latex or
synthetic condom during any sexual contact with females of
reproductive potential while taking POMALYST and for up to 4 weeks
after discontinuing POMALYST, even if they have undergone a successful
vasectomy. Males must not donate sperm.
- Males: Pomalidomide is present in the
-
- Blood Donation: Patients must not donate
blood during treatment with POMALYST and for 4 weeks following
discontinuation of POMALYST therapy because the blood might be given
to a pregnant female patient whose fetus must not be exposed to
POMALYST.
- Blood Donation: Patients must not donate
-
- POMALYST REMS®
Program: See Boxed WARNINGS
- POMALYST REMS®
-
- Prescribers and pharmacies must be certified with the POMALYST REMS
program by enrolling and complying with the REMS requirements;
pharmacies must only dispense to patients who are authorized to
receive POMALYST. Patients must sign a Patient-Physician Agreement
Form and comply with REMS requirements; female patients of
reproductive potential who are not pregnant must comply with the
pregnancy testing and contraception requirements and males must comply
with contraception requirements.
- Prescribers and pharmacies must be certified with the POMALYST REMS
-
- Further information about the POMALYST REMS program is
available at www.CelgeneRiskManagement.com
or by telephone at 1-888-423-5436.
- Further information about the POMALYST REMS program is
-
- Venous and Arterial Thromboembolism: See
Boxed WARNINGS. Patients with known risk factors, including
prior thrombosis, may be at greater risk, and actions should be taken
to try to minimize all modifiable factors (e.g., hyperlipidemia,
hypertension, smoking). Thromboprophylaxis is recommended, and the
choice of regimen should be based on assessment of the patient’s
underlying risk factors.
- Venous and Arterial Thromboembolism: See
-
- Increased Mortality with Pembrolizumab:
In clinical trials in patients with multiple myeloma, the addition of
pembrolizumab to a thalidomide analogue plus dexamethasone resulted in
increased mortality. Treatment of patients with multiple myeloma with
a PD-1 or PD-L1 blocking antibody in combination with a thalidomide
analogue plus dexamethasone is not recommended outside of controlled
clinical trials.
- Increased Mortality with Pembrolizumab:
-
- Hematologic Toxicity:
Neutropenia (46%) was the most frequently reported Grade 3/4 adverse
reaction in patients taking POMALYST in clinical trials, followed by
anemia and thrombocytopenia. Monitor complete blood counts weekly for
the first 8 weeks and monthly thereafter. Patients may require dose
interruption and/or modification.
- Hematologic Toxicity:
-
- Hepatotoxicity: Hepatic
failure, including fatal cases, has occurred in patients treated with
POMALYST. Elevated levels of alanine aminotransferase and bilirubin
have also been observed in patients treated with POMALYST. Monitor
liver function tests monthly. Stop POMALYST upon elevation of liver
enzymes. After return to baseline values, treatment at a lower dose
may be considered.
- Hepatotoxicity: Hepatic
-
- Severe Cutaneous Reactions Including
Hypersensitivity Reactions: Angioedema and severe
cutaneous reactions including Stevens-Johnson Syndrome (SJS), toxic
epidermal necrolysis (TEN), and drug reaction with eosinophilia and
systemic symptoms (DRESS) have been reported. DRESS may present with a
cutaneous reaction (such as rash or exfoliative dermatitis),
eosinophilia, fever, and/or lymphadenopathy with systemic
complications such as hepatitis, nephritis, pneumonitis, myocarditis,
and/or pericarditis. Discontinue POMALYST for angioedema, skin
exfoliation, bullae, or any other severe cutaneous reactions such as
SJS, TEN or DRESS, and do not resume therapy.
- Severe Cutaneous Reactions Including
-
- Dizziness and Confusional State:
In patients taking POMALYST in clinical trials, 14% experienced
dizziness (1% Grade 3 or 4) and 7% a confusional state (3% Grade 3 or
4). Instruct patients to avoid situations where dizziness or
confusional state may be a problem and not to take other medications
that may cause dizziness or confusional state without adequate medical
advice.
- Dizziness and Confusional State:
-
- Neuropathy: In patients
taking POMALYST in clinical trials, 18% experienced neuropathy (2%
Grade 3 in one trial) and 12% peripheral neuropathy.
- Neuropathy: In patients
-
- Second Primary Malignancies: Cases
of acute myelogenous leukemia have been reported in patients receiving
POMALYST as an investigational therapy outside of multiple myeloma.
- Second Primary Malignancies: Cases
-
- Tumor Lysis Syndrome (TLS): TLS
may occur in patients treated with POMALYST. Patients at risk are
those with high tumor burden prior to treatment. These patients should
be monitored closely and appropriate precautions taken.
- Tumor Lysis Syndrome (TLS): TLS
ADVERSE REACTIONS
The most common adverse reactions for POMALYST (≥30%) included fatigue
and asthenia, neutropenia, anemia, constipation, nausea, diarrhea,
dyspnea, upper-respiratory tract infections, back pain, and pyrexia.
In the phase III trial, nearly all patients treated with POMALYST +
low-dose dex experienced at least one adverse reaction (99%). Adverse
reactions (≥15% in the POMALYST + low-dose dex arm and ≥2% higher than
control) included neutropenia (51.3%), fatigue and asthenia (46.7%),
upper respiratory tract infection (31%), thrombocytopenia (29.7%),
pyrexia (26.7%), dyspnea (25.3%), diarrhea (22%), constipation (21.7%),
back pain (19.7%), cough (20%), pneumonia (19.3%), bone pain (18%),
edema peripheral (17.3%), peripheral neuropathy (17.3%), muscle spasms
(15.3%), and nausea (15%). Grade 3 or 4 adverse reactions (≥15% in the
POMALYST + low-dose dex arm and ≥1% higher than control) included
neutropenia (48.3%), thrombocytopenia (22%), and pneumonia (15.7%).
DRUG INTERACTIONS
Avoid concomitant use of POMALYST with strong inhibitors of CYP1A2.
Consider alternative treatments. If a strong CYP1A2 inhibitor must be
used, reduce POMALYST dose by 50%.
USE IN SPECIFIC POPULATIONS
-
- Pregnancy: See Boxed WARNINGS. If
pregnancy does occur during treatment, immediately discontinue the
drug and refer patient to an obstetrician/gynecologist experienced in
reproductive toxicity for further evaluation and counseling. There is
a POMALYST pregnancy exposure registry that monitors pregnancy
outcomes in females exposed to POMALYST during pregnancy as well as
female partners of male patients who are exposed to POMALYST. This
registry is also used to understand the root cause for the pregnancy.
Report any suspected fetal exposure to POMALYST to the FDA via the
MedWatch program at 1-800-FDA-1088 and also to Celgene Corporation at
1-888-423-5436.
- Pregnancy: See Boxed WARNINGS. If
-
- Lactation: There is no
information regarding the presence of pomalidomide in human milk, the
effects of POMALYST on the breastfed child, or the effects of POMALYST
on milk production. Pomalidomide was excreted in the milk of lactating
rats. Because many drugs are excreted in human milk and because of the
potential for adverse reactions in a breastfed child from POMALYST,
advise women not to breastfeed during treatment with POMALYST.
- Lactation: There is no
-
- Pediatric Use: Safety and
effectiveness have not been established in pediatric patients.
- Pediatric Use: Safety and
-
- Geriatric Use: No dosage
adjustment is required for POMALYST based on age. Patients >65 years
of age were more likely than patients ≤65 years of age to experience
pneumonia.
- Geriatric Use: No dosage
-
- Renal Impairment: Reduce
POMALYST dose by 25% in patients with severe renal impairment
requiring dialysis. Take dose of POMALYST following hemodialysis on
hemodialysis days.
- Renal Impairment: Reduce
-
- Hepatic Impairment: Reduce
POMALYST dose by 25% in patients with mild to moderate hepatic
impairment and 50% in patients with severe hepatic impairment.
- Hepatic Impairment: Reduce
-
- Smoking Tobacco: Advise
patients that smoking may reduce the efficacy of POMALYST. Cigarette
smoking reduces the AUC of pomalidomide by 32% by CYP1A2 induction.
- Smoking Tobacco: Advise
Please see full Prescribing
Information, including Boxed WARNINGS.
About Celgene Global Health
Celgene Global Health (CGH) is a dedicated R&D unit of Celgene committed
to discovering, developing and delivering novel drugs for Diseases of
the Developing World (DDWs). Collaborating with non-profit and academic
institutions around the globe, CGH has utilized the company’s library of
more than 400,000 compounds to evaluate candidates for drug development
for DDWs. More than ten discovery and development programs are ongoing
in several disease areas such as malaria and tuberculosis. For more
information, visit https://www.celgene.com/responsibility/global-health/
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global pharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through gene and
protein regulation. For more information, please visit the Company’s
website at www.celgene.com.
Follow Celgene on Social Media: @Celgene,
Pinterest,
LinkedIn,
Facebook
and YouTube.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words “expects,” “anticipates,”
“believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and
similar expressions. Forward-looking statements are based on
management’s current plans, estimates, assumptions and projections, and
speak only as of the date they are made. Celgene undertakes no
obligation to update any forward-looking statement in light of new
information or future events, except as otherwise required by law.
Forward-looking statements involve inherent risks and uncertainties,
most of which are difficult to predict and are generally beyond our
control. Actual results or outcomes may differ materially from those
implied by the forward-looking statements as a result of the impact of a
number of factors, many of which are discussed in more detail in our
Annual Report on Form 10-K and other reports filed with the Securities
and Exchange Commission, including factors related to the proposed
transaction between Bristol-Myers Squibb and Celgene, such as, but not
limited to, the risks that: management’s time and attention is diverted
on transaction related issues; disruption from the transaction makes it
more difficult to maintain business, contractual and operational
relationships; legal proceedings are instituted against Bristol-Myers
Squibb, Celgene or the combined company could delay or prevent the
proposed transaction; and Bristol-Myers Squibb, Celgene or the combined
company is unable to retain key personnel
Contacts
+1-908-673-9628
ir@celgene.com
or
Media:
+1-908-673-2275
media@celgene.com